| Configuration: AlphaFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 7.4 CAPRI interface RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen af3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, iRMSD row, AlphaFold 3 column; Table 1 assessable count |
|---|
| Configuration: AlphaFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 0.88 lDDT fraction · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen af3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, LDDT row, AlphaFold 3 column; Table 1 assessable count |
|---|
| Configuration: AlphaFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 24.5 CAPRI ligand RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen af3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, lRMSD row, AlphaFold 3 column; Table 1 assessable count |
|---|
| Configuration: AlphaFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 47.9% FoldBench success rate percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen af3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, Success rate row, AlphaFold 3 column; Table 1 assessable count |
|---|
| Configuration: Boltz-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 8.8 CAPRI interface RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen boltz1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, iRMSD row, Boltz-1 column; Table 1 assessable count |
|---|
| Configuration: Boltz-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 0.84 lDDT fraction · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen boltz1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, LDDT row, Boltz-1 column; Table 1 assessable count |
|---|
| Configuration: Boltz-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 30.7 CAPRI ligand RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen boltz1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, lRMSD row, Boltz-1 column; Table 1 assessable count |
|---|
| Configuration: Boltz-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 33.5% FoldBench success rate percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen boltz1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, Success rate row, Boltz-1 column; Table 1 assessable count |
|---|
| Configuration: Chai-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 10.5 CAPRI interface RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen chai1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, iRMSD row, Chai-1 column; Table 1 assessable count |
|---|
| Configuration: Chai-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 0.85 lDDT fraction · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen chai1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, LDDT row, Chai-1 column; Table 1 assessable count |
|---|
| Configuration: Chai-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 33.4 CAPRI ligand RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen chai1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, lRMSD row, Chai-1 column; Table 1 assessable count |
|---|
| Configuration: Chai-1 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 23.6% FoldBench success rate percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen chai1 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, Success rate row, Chai-1 column; Table 1 assessable count |
|---|
| Configuration: HelixFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 9.97 CAPRI interface RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen helixfold3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, iRMSD row, HelixFold 3 column; Table 1 assessable count |
|---|
| Configuration: HelixFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 0.84 lDDT fraction · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen helixfold3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, LDDT row, HelixFold 3 column; Table 1 assessable count |
|---|
| Configuration: HelixFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 33 CAPRI ligand RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen helixfold3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, lRMSD row, HelixFold 3 column; Table 1 assessable count |
|---|
| Configuration: HelixFold 3 — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 28.4% FoldBench success rate percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen helixfold3 Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, Success rate row, HelixFold 3 column; Table 1 assessable count |
|---|
| Configuration: Protenix — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 8.91 CAPRI interface RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen protenix Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, iRMSD row, Protenix column; Table 1 assessable count |
|---|
| Configuration: Protenix — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 0.85 lDDT fraction · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen protenix Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, LDDT row, Protenix column; Table 1 assessable count |
|---|
| Configuration: Protenix — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 30.4 CAPRI ligand RMSD angstrom · lower Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen protenix Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, lRMSD row, Protenix column; Table 1 assessable count |
|---|
| Configuration: Protenix — FoldBench published inference | Protocol: FoldBench antibody-antigen published full-set assessment Dataset: FoldBench antibody-antigen published targets | 34.1% FoldBench success rate percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourcefoldbench antibody antigen protenix Not reported Aggregation: source table mean FoldBench supplementary target coverage and performance · Supplementary Table 3, antibody-antigen block, Success rate row, Protenix column; Table 1 assessable count |
|---|